Mdi related products and methods of use

Abstract

Provided herein are embodiments related to metered dose inhalers and formulations for such inhalers. In some embodiments, the inhalers are configured so as to allow a more comfortable experience for the subject receiving the formulation. In some embodiments, the formulation comprises various ingredients, such as terpenes and/or waxes, which can further enhance the level of comfort for the subject receiving the formulation.

1 .- 42 . (canceled) 
     
     
         43 . A formulation for metered dose inhalation, said formulation comprising:
 an extract comprising an amount of at least one cannabinoid, wherein the at least one cannabinoid comprises a cannabidiol (CBD), and wherein the amount of the cannabidiol is at least 0.2 mg/mL and less than 350 mg/mL;   an amount of a propellant suitable for metered dose inhalation application to a human subject, wherein the propellant comprises at least a HFA;   a polar solvent, wherein the polar solvent is miscible with the propellant and the cannabinoid(s), wherein extract: polar solvent: HFA propellant is in a ratio ranging from 0.5:0.5:99 to 30:30:40; and   a terpene, in an amount of at least 3 μg/mL.   
     
     
         44 . The formulation of  claim 43 , wherein the terpene is selected from the group consisting of at least one of: Pinene, Limonene, Myrcene, Phellandrene, Carene, Terpinene, Linalool, Fenchol, Borneol, Terpineol, Geraniol, Humulene, Caryophyllene, Caryophyllene Oxide, Bisabolol, Citronellol, Menthol, Ocimene, Camphene or Phytol. 
     
     
         45 . The formulation of  claim 43 , wherein the at least one cannabinoid further comprises at least one activated cannabinoid. 
     
     
         46 . The formulation of  claim 43 , wherein the at least one cannabinoid further comprises at least one cannabinoid selected from the group consisting of Tetrahydrocannabinol (THC), and Tetrahydrocannabivarin (THCV). 
     
     
         47 . The formulation of  claim 43 , wherein the at least one cannabinoid further comprises THC. 
     
     
         48 . The formulation of  claim 43 , wherein the solvent comprises an amount of ethanol. 
     
     
         49 . The formulation of  claim 48 , where the ethanol is present in an amount of up to 30% w/w. 
     
     
         50 . The formulation of  claim 43 , wherein the HFA is at least one of 1,1,1,2-Tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-Heptafluoropropane (HFA 227ea). 
     
     
         51 . A formulation for metered dose inhalation, said formulation comprising:
 an amount of an activated cannabinoid, wherein the activated cannabinoid comprises at least Tetrahydrocannabinol (THC) and Cannabidiol (CBD), wherein the amount of the Cannabidiol is at least 0.2 mg/mL and less than 350 mg/mL;   an amount of ethanol sufficient to serve as a solvent;   an amount of a propellant, wherein the propellant is at least one of 1,1,1,2-Tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-Heptafluoropropane (HFA 227ea), wherein an extract comprises the activated cannabinoid, and   an amount of a natural terpene, in an amount of at least 3 μg/mL, wherein the natural terpene is one that is present in a cannabis plant, and wherein extract: ethanol: HFA propellant is in a ratio ranging from 0.5:0.5:99 to 30:30:40.   
     
     
         52 . A metered dose inhaler canister comprising:
 a formulation according to  claim 51 ; and   a coating over an interior surface of the canister, wherein the coating comprises at least one of anodized aluminum or a fluoropolymer.   
     
     
         53 . A metered dose inhaler comprising:
 a formulation according to  claim 51 ; and   an actuator drug/propellant pathway, comprising an actuator orifice cylinder configured to provide an appropriate mean mass aerosol diameter (MMAD) particulate size distribution of the formulation, and of sufficient surface area and heat sink properties to provide for single and rapid dispensing cycles of the formulation, and propellant, to maintain dose content uniformity, particle size distribution, and the comfort of the patient; wherein the actuator orifice cylinder is configured by at least one of:
 a) an appropriate surface area, internal geometry jet length or shape, surface texture, or material of the actuator orifice cylinder; or 
 b) an increased mass of the external geometry of the actuator orifice cylinder, as compared to the mass of the external geometry of the actuator orifice cylinder without a heat sink, to act as a heat sink by at least 5% additional mass. 
   
     
     
         54 . The metered dose inhaler of  claim 53 , wherein an increased surface area, as compared to the surface area of the external geometry of the actuator orifice cylinder without a heat sink, is achieved by increasing the texture of the cylinder area by at least one of a cut, a groove, a ridge, or by a mold etched texture. 
     
     
         55 . The metered dose inhaler of  claim 53 , wherein a MDI valve is located between the MDI canister and the orifice cylinder, wherein the MDI valve is configured to dispense between 20 and 125 microliters of formulation per actuation, and wherein the MDI valve is made of at least one of polyoxymethalate (POM), polybutylterephalate (PBT), ABS, acrylic, polycarbonate, ethylene propylene diene monomer (EPDM), or silicon. 
     
     
         56 . The metered dose inhaler of  claim 53 , wherein the appropriate mean mass aerosol diameter (MMAD) particulate size distribution is between 0.5 and 5.0 micron of the formulation. 
     
     
         57 . The formulation of  claim 50 , wherein the CBD, and terpene are from the extract, wherein the extract is plant based, and wherein the solvent is ethanol, and wherein the ethanol is present in an amount of up to 30% w/w.